Abstract:Background The pathogenesis of Cushing's disease (CD) is still not adequately understood despite the identification of somatic driver mutations in USP8, BRAF, and USP48. In this multiomics study, we combined RNA sequencing (RNA-seq) with Sanger sequencing to depict transcriptional dysregulation under different gene mutation backgrounds. Furthermore, we evaluated the potential of achaete-scute complex homolog 1 (ASCL1), a pioneer transcription factor, as a novel therapeutic target for treatment of CD and its possible downstream pathway. Methods RNA-seq was adopted to investigate the gene expression profile of CD, and Sanger sequencing was adopted to detect gene mutations. Bioinformatics analysis was used to depict transcriptional dysregulation under different gene mutation backgrounds. The function of ASCL1 in hormone secretion, cell proliferation, and apoptosis were studied in vitro. The effectiveness of an ASCL1 inhibitor was evaluated in primary CD cells, and the clinical relevance of ASCL1 was examined in 68 patients with CD. RNA-seq in AtT-20 cells on Ascl1 knockdown combined with published chromatin immunoprecipitation sequencing data and dual luciferase assays were used to explore downstream pathways. Results ASCL1 was exclusively overexpressed in USP8-mutant and wild-type tumors. Ascl1 promoted adrenocorticotrophin hormone overproduction and tumorigenesis and directly regulated Pomc in AtT-20 cells. An ASCL1 inhibitor presented promising efficacy in both AtT-20 and primary CD cells. ASCL1 overexpression was associated with a larger tumor volume and higher adrenocorticotrophin secretion in patients with CD. Conclusion Our findings help to clarify the pathogenesis of CD and suggest that ASCL1 is a potential therapeutic target the treatment of CD. The pathogenesis of Cushing's disease (CD) is still not adequately understood despite the identification of somatic driver mutations in USP8, BRAF, and USP48. Moreover, few effective medical therapies are currently available for the treatment of CD. Here, using a multiomics approach, we first report the aberrant overexpression of the transcription factor gene ASCL1 in USP8-mutant and wild-type tumors of CD. Ascl1 promoted adrenocorticotrophin hormone overproduction and tumorigenesis and directly regulated Pomc in mouse AtT-20 cells. Notably, an ASCL1 inhibitor presented promising efficacy in both AtT-20 and primary CD cells. Importantly, ASCL1 overexpression was associated with a larger tumor volume and higher adrenocorticotrophin secretion in patients with CD. Thus, our findings improve understanding of CD pathogenesis and suggest that ASCL1 is a potential therapeutic target the treatment of CD.

Author Correction: Identification of recurrent USP48 and BRAF mutations in Cushing's disease

Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients (vol <i>11</i>, <i>655709</i>, <i>2021</i>)

Recurrent Gain-Of-Function Usp8 Mutations in Cushing'S Disease

Corrigendum: Genome-wide Association Study of Esophageal Squamous Cell Carcinoma in Chinese Subjects Identifies Susceptibility Loci at PLCE1 and C20orf54

Author Correction: BHMT Polymorphism and Susceptibility to PTE in Chinese Patients.

Corrigendum: Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients

Transcription Factor ASCL1 Acts as a Novel Potential Therapeutic Target for the Treatment of the Cushing's Disease

Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas

Correction: Publisher Correction: Simultaneous Overactivation of Wnt/β-catenin and TGFβ Signalling by Mir-128-3p Confers Chemoresistance-Associated Metastasis in NSCLC

Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Corrigendum: Molecular Portrait of GIST Associated With Clinicopathological Features: A Retrospective Study With Molecular Analysis by a Custom 9-Gene Targeted Next-Generation Sequencing Panel

Corrigendum: Sequential PET/CT and pathological biomarker crosstalk predict response to PD-1 blockers alone or combined with sunitinib in propensity score-matched cohorts of cancer of unknown primary treatment

Author Correction: Identification of Novel Genetic Variants Predisposing to Familial Oral Squamous Cell Carcinomas

Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer

Author Correction: Reprogramming of palmitic acid induced by dephosphorylation of ACOX1 promotes β-catenin palmitoylation to drive colorectal cancer progression

Corrigendum: Immune regulation and prognostic prediction model establishment and validation of PSMB6 in lung adenocarcinoma

Author Correction to “Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy” [acta Pharm Sin B 12 (2022) 4224–4234]

Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts

Erratum: Author Correction to "Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy" [acta Pharm Sin B (2022) 4224-4234].

Author Correction: Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients

Correction To: Identification of TAZ As the Essential Molecular Switch in Orchestrating SCLC Phenotypic Transition and Metastasis.